Notification of interruption to supply

20 March 2017

RANZCOG has been notified by Pfizer that due to manufacturing issues, the current stock of PROSTIN® E2 VAGINAL GEL 2mg is expected to be depleted by the end of March 2017, and availability of new stock is not expected until May 2017. There is no safety concern with this medicine.
Vaginal dinoprostone is available from another manufacturer.
Full Product Information for PROSTIN® E2 VAGINAL GEL can be accessed at
For any medical enquiries regarding PROSTIN® E2 VAGINAL, contact Pfizer Medical Information on 1800 675 229.
As RANZCOG recognises the potential impact this may have on your practice, to hospital departments across Australia, and to the women in your care, we are endeavouring to ensure all members are made aware of this important issue through multiple communication channels.




Reproductive Health Care Reform Bill 2019: proposed amendments

The proposed amendments call into question the standards and ethics of the medical profession, seeking to regulate and control practice.



Reproductive Health Care Reform Bill 2019

RANZCOG recognises the complexities associated with late term abortions, and supports a process by which late term abortions can be lawfully performed where appropriate.



Reproductive Health Care Reform Bill 2019

The peak body for obstetrics and gynaecology and women’s health, RANZCOG, welcomes the tabling of the Reproductive Health Care Reform Bill 2019 in the NSW Parliament and urges all MPs to vote in favour.